Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso La… (NCT07701161) | Clinical Trial Compass
RecruitingNot Applicable
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
United States1,000 participantsStarted 2025-01-13
Plain-language summary
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
Who can participate
Age range
40 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed
Exclusion Criteria:
* Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is testing a home finger-prick blood device to measure a protein called p-tau217 — can you explain what p-tau217 is and how it relates to my diagnosis or risk of Alzheimer's disease?
2The main goal of this study is to compare results from the home Tasso lancet device against a standard blood draw — so participants aren't being treated, just having blood measured in two ways. Is that right, and does that change whether it might be worth my time to take part?
3Since this is listed as Phase NA, which suggests it's a device validation study rather than a treatment trial, would joining this study have any impact on my access to standard care or other treatment options you might recommend for me?
4How would I actually use the Tasso device at home — do I need to do the blood collection myself, and is that something you think would be manageable given my current situation?
5Are there other ways my p-tau217 levels might already be measured as part of my regular care, and how would joining this study compare to or overlap with those existing tests?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Agreement between p-tau217 concentration in Tasso device capillary blood and venipuncture blood